1. Peanut Allergy Immunotherapy

3. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Peanut Allergy Immunotherapy

5. Unmet Need Peanut Allergy Treatment

6. Emerging Peanut Allergy Immunotherapies

7. PALISADE Phase 3 Trial Trial Design

8. PALISADE Phase 3 Trial Efficacy: ITT Population

9. PALISADES Phase 3 Trial Safety Results

10. PALISADES Phase 3 Trial Safety Results (cont)

11. PALISADES Phase 3 Trial Safety Results (cont)

12. PALISADES Phase 3 Trial Withdrawal Rates

13. PEPITES and PEOPLE Trial Design

14. PEPITES Trial Results

15. PEPITES Trial Safety Results

16. PEPITES Trial Secondary Efficacy Results

17. Real-World Benefits of EPIT Risk Reduction of Allergic Reactions

18. Options for Decreasing Risk of Allergic Reactions

19. Therapy Selection Considerations

20. Preparing Your Practice for Immunotherapy

21. Preparing Your Practice for Immunotherapy (cont)

22. Faculty Predictions for 2019

23. Concluding Remarks

24. Abbreviations